Please assess the completion status of the following clinical trial:

Trial Title: Cancer Screening Program for Women at High Risk for Developing Ovarian Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Must meet one of the following:~  * The family contains at least two ovarian or breast cancers in the subject or first or second degree relatives of the subject.~ * The subject is of Ashkenazi Jewish ethnicity with one first degree or two second-degree relatives with breast or ovarian cancer, or subject is of Ashkenazi ancestry and has had breast cancer.~ * The subject has a male relative with breast cancer diagnosed at any age.~ * Probability of carrying a BRCA1/2 mutation given family pedigree of breast and ovarian cancers exceeds 20% (as determined by BRCAPRO 95% posterior probability interval).~Exclusion Criteria:~* Prior ovarian cancer or peritoneal carcinomatosis~* A first or second degree relative with a BRCA1/2 mutation and has tested negative for exactly the same mutation.~* The subject has no ovaries.~* Less than 30 years of age, unless 25-30 with BRCA I or II mutation confirmed~* Currently pregnant~* Currently receiving adjuvant chemotherapy or radiation therapy for cancer (excluding tamoxifen). Patients who are being treated for local disease may enroll 3 months after completion of last treatment (excluding tamoxifen).~* Treatment (excluding tamoxifen) for prior metastatic malignancy within the past five years.~* Intraperitoneal surgery within the last 3 months.

- Gender: FEMALE
- Minimum Age: 30 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Ovarian Cancer Screening (Type: EXPERIMENTAL): CA125 tumor marker, Transvaginal Ultrasound, Health Status Questionnaires

Based on this trial design, predict the completion outcome and termination type (if applicable).